Clinical trial NCT03892876: Trial of Stimulus-response Potentiation in Schizophrenia
Official title: Pilot Trial of Stimulus-response Potentiation in Schizophrenia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Schizophrenia
Lead sponsor: Cairo University
Sponsor class: OTHER
Collaborators: name: University of Pittsburgh
First posted: 2019-03-27
Enrollment: 120
Sex: MALE
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This clinical trial aims at examining the effects of auditory high-frequency stimulation in schizophrenia patient, aiming to increase their AEPs, which are known to be attenuated from previous literature

Detailed description: Schizophrenia is a chronic psychiatric disorder with a lifetime prevalence of 4.0 per 1,000. The introduction of antipsychotic medications in the 1950s resulted in marked clinical improvement in the symptom profile of schizophrenia, nevertheless the disease still contributes to a significant proportion of global disease burden in terms of both morbidity and mortality. In this regard, cognitive deficits and residual negative symptoms are considered major contributing factors to psychosocial disability and poor functional outcome associated with the disorder.

Higher-order cognitive functions; e.g. working memory and executive functions; show variable deficits and are considered a core clinical symptom of schizophrenia. On the other hand, the disorder is also characterized by abnormalities at the basic level of primary sensory processing, i.e. auditory, visual and somatosensory processing. Such abnormalities in the primary process of sensory perception could change the sensory experiences of schizophrenia patients and thus contribute to the psychopathology.

Event-related potentials (ERPs) are the neurophysiological correlates of sensory processing. ERP abnormalities have been widely described in schizophrenia literature: Pre-pulse inhibition of startle (PPI) in which a weaker pre-stimulus (pre-pulse) inhibits the reaction to a subsequent strong startling stimulus (pulse) is impaired in schizophrenia. P50 suppression, a measure of sensory gating, is also often absent or reduced in the disorder. N100; a measure of basic auditory sensory perception; shows significant amplitude reduction in patients compared to controls. Mismatch negativity (MMN), a measure of automatic deviance detection and shows characteristic attenuation in schizophrenia. P300, which is involved in higher-level stimulus evaluation and categorization, also shows abnormalities along the disease course.

In the study by Clapp et al., 2005, auditory high frequency stimulation (tetanizing stimulation) resulted in an increase in auditory-evoked potentials (AEPs) in healthy individuals; i.e. an increase in N1 amplitude that persisted even after stimulation. This augmentation of N1 amplitude was regarded as a result of plastic synaptic potentiation similar to long-term potentiation (LTP) described after electrical tetanic stimulation in cellular studies. Similar findings were later replicated by Lei et al., 2017, where they used pure tones, narrow band noises and white noise to induce stable potentiation and augmentation of N1 amplitude.

Eligibility criteria: For Schizophrenia group:

Inclusion Criteria:

* Able to give written informed consent
* Males (ages 20-50 years)
* Diagnosis of schizophrenia as confirmed by Structured Clinical Interview for DSM-V-TR (SCID)
* on stable doses of antipsychotic medications for at least 15 days
* scores 4 or more on at least one item of the Positive and Negative Syndrome Scale.

Exclusion Criteria:

* History of / or current medical/neurological illnesses e.g. mental retardation (DSM-V) or epilepsy or significant head trauma
* Any type of hearing deficit will be excluded by audiometry assessment
* Substance abuse in the past 2 months
* medical conditions that make it difficult for the patient to visit the clinic in the designed schedule.

For control group:

Inclusion criteria:

* able to give written informed consent
* males (ages 20-50).

Exclusion criteria:

* History of / or current medical/neurological illnesses e.g. mental retardation (DSM-V) or epilepsy or significant head trauma
* Any type of hearing deficit
* if they meet any axis-I diagnosis according to DSM-V confirmed by SCID.
* scores 2 or more on one item of the Positive and Negative Syndrome Scale

Primary outcomes:
measure: N100 wave (AEP) amplitude in µv [microvolts]
timeFrame: 1-2 hours
measure: P300 wave amplitude in µv [microvolts] (auditory odd-ball task)
timeFrame: 1-2 hours
Secondary outcomes:
measure: performance of Wisconsin Card Sorting test (WCST).
timeFrame: 3 days
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Department of Psychiatry-Faculty of medicine-University of Cairo
state: Cairo Governerate
Study officials:
affiliation: Department of Psychiatry-University of Cairo
name: Ola O Shahin, MD
role: STUDY_DIRECTOR
affiliation: Department of Psychiatry-University of Pittsburgh
name: Vishwajit L Nimgaonkar, PhD
role: STUDY_DIRECTOR
References: